WOBURN, MA / ACCESSWIRE / March 2, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products will be presenting at the 35th Annual ROTH Conference in Laguna Nigel, CA being held March 12-14, 2023. Biofrontera, Inc. Chief Executive Officer, Erica Monaco, and Chief Financial Officer, Fred Leffler will represent the company at the conference.
The company presentation will be on March 13, 2023 at 8:00 AM PT and the webcast can be viewed here https://wsw.com/webcast/roth46/b8f.de/1934305. An archive of this webcast will also be available soon after the live presentation. Management will be available for 1x1 meetings during the conference. Please contact your ROTH MKM representative to schedule a meeting.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.
Contacts:
Biofrontera Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.86 |
Daily Change: | 0.02 2.61 |
Daily Volume: | 63,348 |
Market Cap: | US$8.110M |
May 15, 2025 March 21, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load